[CH3:1][N:2]1[CH:6]([C:7]([OH:9])=O)[CH2:5][NH:4][C:3]1=[O:10].ON1C2C=CC=CC=2N=N1.Cl.CN(C)CCCN=C=NCC.[Cl:33][C:34]1[C:39]([C:40]([F:43])([F:42])[F:41])=[CH:38][CH:37]=[CH:36][C:35]=1[CH2:44][NH2:45].C(N1CCOCC1)C>CN(C)C=O>[Cl:33][C:34]1[C:39]([C:40]([F:42])([F:43])[F:41])=[CH:38][CH:37]=[CH:36][C:35]=1[CH2:44][NH:45][C:7]([CH:6]1[CH2:5][NH:4][C:3](=[O:10])[N:2]1[CH3:1])=[O:9]Crude 3-methyl-2-oxo-4-imidazolidinecarboxylic acid (˜0.63 mmol, prepared as described below) was dissolved in dimethylformamide (3 ml) and treated with 1-hydroxybenzotriazole (0.094 g, 0.69 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (0.132 g, 0.69 mmol), [(2-chloro-3-trifluoromethylphenyl)methyl]amine (0.145 g, 0.69 mmol) and N-ethylmorpholine (0.169 ml, 1.32 mmol). The mixture was stirred at 22° C. for 20 hours then reduced in vacuo to give a residue which was purified by mass-directed automated HPLC to give N-{[2-chloro-3-(trifluoromethyl)phenyl]methyl}-3-methyl-2-oxo-4-imidazolidinecarboxamide as a white solid (0.105 g). LC/MS [M+H]+=336, retention time=2.18 minutes.